Take a look at our previous reports:

Annual Report 2025

31. Off-Balance Sheet Arrangements

Contractual obligations and commitments

On December 31, 2025, we had outstanding obligations for future purchase commitments, which become due as follows:

Contractual obligations and commitments – 2025 – Purchase commitments

(thousands of €)

Total

Less than
1 year

1 – 3 years

3 – 5 years

More than
5 years

Purchase commitments

91,344

75,845

13,858

1,556

85

On December 31, 2024, we had outstanding obligations for future purchase commitments, which become due as follows:

Contractual obligations and commitments – 2024 – Purchase commitments

(thousands of €)

Total

Less than
1 year

1 – 3 years

3 – 5 years

More than
5 years

Purchase commitments

272,240

189,662

70,323

10,962

1,293

Our purchase commitments at the end of the year 2025 were adjusted considering the wind-down of the cell therapy activities and included €61.7 million related to projects in development phase (2024: €160.9 million), €2.5 million for projects in discovery research phase (2024: €60.9 million), €25.2 million for shared services (2024: €46.0 million), €0.4 million for commercial and medical affairs (2024: €1.7 million), and €1.6 million related to product supply chain (2024: €2.6 million).

Cell therapy
Cell therapy aims to treat diseases by restoring or altering certain sets of cells or by using cells to carry a therapy through the body. With cell therapy, cells are cultivated or modified outside the body before being injected into the patient. The cells may originate from the patient (autologous cells) or a donor (allogeneic cells)
Discovery
Process by which new medicines are discovered and/or designed. At Galapagos, this is the department that oversees target and drug discovery research through to nomination of preclinical candidates